FBRX

Forte Biosciences Inc

Apr 09 • 04:00PM ET

33.90

+7.63 29.04 %

Healthcare • Biotechnology • USA • NASD

Apr 08, 9:35 PMForte Biosciences prices $150 million underwritten public offering of 5.7 million common shares at $26.27 per share

Peers: FOLD MRNS AGEN BGMS CGEM GERN AKBA CLSD ARMP DYAI

| Held by: VTI VXF ATFV IWC SBIO AVSC RUSC TXS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.24	Insider Own	13.08%	Shs Outstand	12.95M	Perf Week	36.36%
Market Cap	470.73M	Forward P/E	-	EPS next Y	-4.32	Insider Trans	0.54%	Shs Float	12.07M	Perf Month	19.92%
Enterprise Value	393.77M	PEG	-	EPS next Q	-1.16	Inst Own	81.12%	Short Float	6.03%	Perf Quarter	28.90%
Income	-69.38M	P/S	-	EPS this Y	7.90%	Inst Trans	4.84%	Short Ratio	3.18	Perf Half Y	138.23%
Sales	0.00M	P/B	7.20	EPS next Y	0.37%	ROA	-96.13%	Short Interest	0.73M	Perf YTD	24.31%
Book/sh	4.71	P/C	6.12	EPS next 5Y	3.67%	ROE	-122.28%	52W High	35.62 -4.83%	Perf Year	494.74%
Cash/sh	5.54	P/FCF	-	EPS past 3/5Y	38.19% 50.46%	ROIC	-113.75%	52W Low	4.90 591.84%	Perf 3Y	24.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.50% 11.03%	Perf 5Y	-96.58%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	68.18%	Oper. Margin	-	ATR (14)	3.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.88	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	69.87	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.88	EPS Q/Q	-71.07%	SMA20	28.80%	Beta	3.21	Target Price	63.75
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	19.17%	Rel Volume	11.99	Prev Close	26.27
Employees	19	LT Debt/Eq	0.00	Earnings	Mar 31 AMC	SMA200	76.51%	Avg Volume	228.61K	Price	33.90
IPO	Apr 13, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.80% -	Trades		Volume	2,740,613	Change	29.04%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Initiated	Evercore ISI	Outperform	$65
Aug-18-25	Initiated	Guggenheim	Buy	$75
Jan-21-25	Initiated	TD Cowen	Buy
Apr-08-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$2.75
Sep-20-21	Upgrade	Chardan Capital Markets	Sell → Buy	$4 → $3.50
Sep-03-21	Downgrade	Truist	Buy → Hold	$4
Sep-03-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-03-21	Downgrade	Chardan Capital Markets	Buy → Sell	$105 → $4
Sep-03-21	Downgrade	B. Riley Securities	Buy → Neutral	$3
May-14-21	Initiated	B. Riley Securities	Buy	$73
Mar-26-21	Initiated	Citigroup	Buy	$75
Aug-28-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$45
Aug-25-20	Initiated	Truist	Buy	$70

Show Previous Ratings

Apr-08-26 09:30PM	Forte Biosciences Announces Pricing of $150 Million Public Offering (Business Wire) +29.04%
04:02PM	Forte Biosciences Announces Proposed Public Offering (Business Wire)
Mar-31-26 04:01PM	Forte Biosciences, Inc. Announces 2025 Results and Provides Update (Business Wire)
Mar-17-26 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) -6.01%
Mar-04-26 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules (Business Wire)
12:00PM	Loading…
Feb-25-26 12:00PM	Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-09-26 04:01PM	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings (Business Wire) +8.05%
Dec-22-25 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire) -9.15%
Nov-24-25 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire)
Nov-14-25 09:00AM	Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update (Business Wire)
Nov-03-25 04:01PM	Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences (Business Wire) -8.96% -7.39%
Oct-03-25 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) +15.25% -6.84%
Sep-15-25 09:00AM	Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium (Business Wire) +8.71%
Aug-14-25 04:01PM	Forte Biosciences, Inc. Announces Results and Provides Update (Business Wire) +6.93%
Jun-25-25 12:28AM	Forte Biosciences Announces Pricing of $75 Million Public Offering (Business Wire) -25.26%
04:01PM	Loading…
Jun-24-25 04:01PM	Forte Biosciences Announces Proposed Public Offering (Business Wire) +11.05%
01:06PM	Forte Biosciences announces data from trial in celiac disease for FB102 (TipRanks)
Jun-23-25 07:18AM	Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study (Business Wire) -12.96%
May-15-25 04:01PM	Forte Biosciences, Inc. Announces Results and Provides Update (Business Wire)
Apr-03-25 12:00PM	All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy (Zacks) -10.48%
Mar-31-25 09:00AM	Forte Biosciences, Inc. Announces Results and Provides Clinical Update (Business Wire) -5.37%
Feb-03-25 09:00AM	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings (Business Wire) -5.79%
Nov-25-24 09:00AM	Forte Biosciences to Host RandD Day December 3, 2024 (Business Wire)
09:00AM	Forte Biosciences to Host R&D Day December 3, 2024 (Business Wire)
Nov-20-24 09:00AM	Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications (Business Wire) +128.69%
Nov-14-24 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update (Business Wire)
Aug-26-24 11:51AM	Upcoming Stock Splits This Week (August 26 to August 30) Stay Invested (TipRanks) +6.44%
Aug-14-24 09:54PM	FBRX Stock Earnings: Forte Biosciences Misses EPS for Q2 2024 (InvestorPlace) -7.80% -20.51%
04:01PM	Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update (Business Wire)
Jul-15-24 10:26AM	Is Forte Biosciences, Inc. (FBRX) One of the Best Penny Stocks to Buy Now Under $1? (Insider Monkey)
09:35AM	Loading…
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
May-17-24 04:05PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
May-13-24 09:54PM	FBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024 (InvestorPlace)
04:05PM	Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update (Business Wire)
Mar-25-24 12:00PM	What Makes Forte Biosciences (FBRX) a New Buy Stock (Zacks)
Mar-19-24 06:53AM	FBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023 (InvestorPlace)
Mar-18-24 04:05PM	Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update (Business Wire)
Dec-04-23 07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Dec-01-23 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire) +5.06%
Nov-13-23 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update (Business Wire) -9.47%
Sep-14-23 10:50AM	ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Companys Upcoming Annual Meeting (Business Wire)
Sep-06-23 03:15PM	Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Companys Boardroom (Business Wire)
Aug-25-23 08:00AM	Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders (Business Wire)
Aug-14-23 04:01PM	Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update (Business Wire) -6.93%
Aug-01-23 04:01PM	Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102 (Business Wire) -5.65%
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
May-19-23 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire)
May-15-23 04:01PM	Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update (Business Wire)
Mar-31-23 04:05PM	Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update (Business Wire)
Jan-12-23 04:05PM	Mr. David Gryska Appointed to Forte Biosciences Board of Directors (Business Wire)
Nov-14-22 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update (Business Wire)
04:01PM	Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors (Business Wire)
Aug-17-22 08:00AM	Camac Partners Condemns Forte Biosciences Seemingly Defensive and Unjustifiable Capital Raise (Business Wire)
Aug-15-22 04:05PM	Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update (Business Wire)
Jul-08-22 07:16AM	We're Keeping An Eye On Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate (Simply Wall St.) +6.99%
Jun-07-22 09:00AM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) +10.17%
09:00AM	Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President (Business Wire)
May-16-22 09:00AM	Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update (Business Wire) -8.90%
Dec-15-21 05:55AM	Here's Why We're Watching Forte Biosciences' (NASDAQ:FBRX) Cash Burn Situation (Simply Wall St.) -5.16%
Sep-09-21 06:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. FBRX (GlobeNewswire)
Sep-08-21 08:51AM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm (Business Wire)
Sep-07-21 09:40PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. FBRX (ACCESSWIRE) -17.19%
Sep-06-21 12:42PM	INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm (Newsfile)
Sep-03-21 07:42PM	INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm (Business Wire) -82.30% -17.19%
02:14PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX (PR Newswire)
11:15AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Forte Biosciences, Inc. (FBRX) Investigation (ACCESSWIRE)
Sep-02-21 04:05PM	Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance (Business Wire)
Aug-16-21 04:05PM	Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7 (Business Wire) -6.11% +12.23%
Aug-02-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
Jul-12-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) -7.72%
Jul-07-21 10:02AM	Implied Volatility Surging for Forte Biosciences (FBRX) Stock Options (Zacks) -7.57%
Jul-01-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
May-14-21 03:06AM	Read This Before Selling Forte Biosciences, Inc. (NASDAQ:FBRX) Shares (Simply Wall St.)
May-10-21 04:05PM	Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update (Business Wire)
02:30PM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)
May-03-21 04:30PM	Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update (Business Wire) -5.36%
Mar-25-21 08:42AM	Forte Posts Lower-Than-Feared Quarterly Loss; Shares Drop 9.5% (SmarterAnalyst) +15.63%
Mar-24-21 08:00AM	Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update (Business Wire) -9.52%
06:30AM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)
Mar-17-21 04:05PM	Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update (Business Wire) -5.36%
Feb-23-21 04:01PM	Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th (Business Wire)
Feb-18-21 04:01PM	Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st (Business Wire) -9.24% +5.27%
Feb-13-21 03:18AM	What Kind Of Investors Own Most Of Forte Biosciences, Inc. (NASDAQ:FBRX)? (Simply Wall St.)
Feb-12-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
Dec-02-20 11:26PM	Is Forte Biosciences (FBRX) A Good Stock To Buy Now? (Insider Monkey) +5.81%
Nov-24-20 04:05PM	Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd (Business Wire) -5.33%
Nov-16-20 04:05PM	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules (Business Wire) +11.24%
Nov-15-20 09:00AM	Read This Before Selling Forte Biosciences, Inc. (NASDAQ:FBRX) Shares (Simply Wall St.)
Nov-10-20 04:05PM	Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th (Business Wire)
Nov-09-20 04:05PM	Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update (Business Wire)
02:30PM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)
Nov-02-20 04:30PM	Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9 (Business Wire) -9.69%
04:05PM	Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Oct-29-20 08:00AM	Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock (Business Wire) +26.94%
Oct-28-20 04:09PM	Forte Biosciences Announces Proposed Public Offering of Common Stock (Business Wire) -15.51%
Oct-26-20 08:30AM	Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis (Business Wire)
Sep-29-20 09:00AM	Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis (Business Wire)
Sep-16-20 08:48AM	We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely (Simply Wall St.) +5.05%
Sep-09-20 04:01PM	Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine (Business Wire) +9.47% +11.13%
Aug-25-20 08:30AM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) +6.32%

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wagner Paul A.	SEE REMARKS	Jan 01 '26	Option Exercise	0.00	1,250	0	83,342	Jan 02 04:07 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Jan 01 '26	Option Exercise	0.00	375	0	41,895	Jan 02 04:04 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Dec 30 '25	Buy	26.33	9,680	254,833	41,520	Jan 02 04:04 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Oct 01 '25	Option Exercise	0.00	375	0	31,974	Oct 02 04:10 PM
Wagner Paul A.	SEE REMARKS	Oct 01 '25	Option Exercise	0.00	1,250	0	82,190	Oct 02 04:09 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Jul 01 '25	Option Exercise	0.00	375	0	31,733	Jul 03 04:22 PM
Wagner Paul A.	SEE REMARKS	Jul 01 '25	Option Exercise	0.00	1,250	0	81,038	Jul 03 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBRX

Forte Biosciences Inc

Upgrade your Finviz experience